引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 189次   下载 34 本文二维码信息
码上扫一扫!
TACE联合阿帕替尼治疗中晚期原发性肝癌的临床疗效分析
徐勤,高珊,缪继东,宋怡兵
0
(自贡市第四人民医院肿瘤科;自贡市第四人民医院耳鼻喉科)
摘要:
【摘要】 目的 观察中晚期原发性肝癌(hepatocellular carcinoma,HCC)患者应用经皮肝动脉介入化疗栓塞术(transcatheter arterial chemoembolization,TACE)后联合使用阿帕替尼的临床疗效,并与联合索拉非尼进行对比。方法 将42例中晚期原发性肝癌患者分为两组,介入化疗栓塞加阿帕替尼联合治疗(实验组)及介入化疗栓塞加索拉非尼联合治疗(对照组)各21例,对两组间临床疗效、AFP、不良反应进行分析比较。结果 实验组客观缓解率、疾病控制率、1年生存率与对照组相比差异无统计学意义(P>005);两组间不良反应比较,实验组出现高血压、皮肤粘膜反应高于对照组,差异有统计学意义(P<005),不良反应经对症处理后均缓解;治疗后3月两组甲胎蛋白均较治疗前明显下降,差异有统计学意义(P<005),实验组甲胎蛋白下降幅度与对照组相比差异无统计学意义(P>005)。结论 肝动脉介入化疗栓塞术后联合使用阿帕替尼或索拉非尼治疗中晚期原发性肝癌,其临床获益率均较高,可明显降低甲胎蛋白,不良反应可控,值得临床推广应用。
关键词:  原发性肝癌  肝动脉插管介入化疗栓塞术  索拉替尼  阿帕替尼  临床疗效
DOI:
基金项目:
Clinical efficacy of apatinib combined with TACE on treatment of primary liver cancer
XU Qin,GAO Shan,MIAO Jidong,SONG Yibing
(Department of Oncology, Zigong Fourth People’s Hospital;Department of Otolaryngology, Zigong Fourth People’s Hospital)
Abstract:
【Abstract】 Objective To observe the clinical efficacy in patients with middleadvanced primary liver cancer treated with TACE combined with apatinib. Methods 42 patients with the middleadvanced primary liver cancer were divided into the treatment group (apatinib combined with TACE) and the control group (sorafenib combined with TACE). The clinical efficacy, the expression of AFP and adverse reactions were observed. Results No statiscally significant differences were found in ORR, DCR and 1 year survival rate between the two groups (P>005). The adverse reactions including hypertension, skin mucosal reaction in the treatment group were higher than those in the control group (P<005). The adverse reactions were relieved after symptomatic treatment. The descent range of AFP 3 month after treatment of the two group was higher than that before treatment (P<005). While no statistic differences were obtained in the descent range of AFP between the treatment group and the control group (P>005).Conclusion Apatinib combined with TACE in the treatment of liver cancer is helpful to improve the DCR and decrease the expression of AFP. The clinical efficacy is not inferior to Sorafenib combined with TACE, and it is a good choice for treatment of middleadvanced primary liver cancer.
Key words:  Primary liver cancer  Transcatheter arterial chemoembolization  Sorafenib  Apatinib  Clinical efficacy

用微信扫一扫

用微信扫一扫